Biopharma Solutions
What We Offer ?
Burning Rock focuses on providing comprehensive cancer genomic solutions for pharmaceutical companies from biomarker discovery to commercialization. Powered by our multimodal central lab testing, integrated companion diagnostic development and commercialization, Burning Rock facilitates the entire process of anti-cancer drug development.
Genomic Data Solutions
Multi-dimensional genomic data from > 590K cases of cancer patients in China
Clinical Trial Solutions
Multimodel central lab testing 200+ Clinical Studies
CDx Development & Commercialization
Integrated companion diagnostic development and commercialization
Precision Patient Recruitment
BR-Domestic Database & BR-LAVA platform
Genomic Data Solutions
Burning Rock utilizes our own proprietary large-scale genomic dataset based on personalized analyses of Chinese cancer patients, integrates the experience from multi-dimensional clinical/scientific research and published data, to provide a one-stop cancer genomic data solution for biopharma partners, with the aim to speed up precision drug development and reduce the risks.
-
Cancer genomics guided indication selection
-
Biomarker discovery for patient stratification
-
Commercial evaluation for targeted detection
-
Site selection based on geographic distribution
Testing Data
Biopharma partners
Publications
Collaborating hospitals
Cancer types
Drug clinical trials
Clinical Trial Solutions
Burning Rock offers integrated central lab services for biopharma partners, from multimodal sample testing to data analysis, meeting drug developing requirements, with five industry-leading qualifications (CLIA, CAP, NCCL, NMPA, ISO15189) and a full spectrum of diagnostic products. So far, we have provided central lab services for >70 pharmaceutical companies in >200 clinical research studies, covering clinical study sites globally.
CDx Development & Commercialization
Burning Rock offers integrated companion diagnostic （CDx） development services for biopharma partners to streamline the codevelopment and commercialization of targeted drug and respective CDx. Our US-based lab and R&D team provide additional services to promote drug and CDx co-development worldwide.
Precision Patient Recruitment
Burning Rock assists clinicians in understanding the inclusion criteria of pharmaceutical company, helps on clinical trial initiation via targeting cancer patients with specific biomarkers, with our own proprietary large-scale genomic database and multiple online resources.
Cooperative Partners
AstraZeneca
EpimAb
IMPACT
KELUN
Allist
FOSUNPHARMA
TopAlliance
Roche
BeiGene
HUTCHMED
CSTONE
REMEGEN
BAYER
HENGRUI
johnson&johnson
CSPC
AnHeart
Abbisko
Lilly
Innovent
Dizal
HANSOH PHARMA
MERCK
inxmed